<DOC>
	<DOCNO>NCT01245426</DOCNO>
	<brief_summary>This randomise , double-blind , placebo-controlled , parallel group study determine efficacy twenty-seven day- repeat inhale daily dos GW870086X force expiratory volume 1 second ( FEV1 ) . Initially 3 treatment arm ; placebo , 2mg GW870086X 4mg GW870086X . After interim analysis trial may ; continue completion use original dos , terminate early , fourth arm add either 1mg GW870086X daily 3mg GW870086X daily .</brief_summary>
	<brief_title>A Study Asthmatics Determine Efficacy Dose Response Repeat Doses GW870086X Forced Expiratory Volume 1 Second ( FEV1 )</brief_title>
	<detailed_description>This randomise , double-blind , placebo-controlled , parallel group study determine efficacy twenty-seven day- repeat inhaled dos GW870086X FEV1 . GW870086X novel inhale corticosteroid potent glucocorticoid activity currently development GlaxoSmithKline ( GSK ) inhale treatment persistent asthma . Initially , subject randomise receive placebo , 2mg 4mg GW870086X daily . An interim analysis perform primary endpoint potentially adapt study design approximately 45 subject complete dose . Based result interim analysis , trial may continue completion use original dos adaptation dos could make . Either 1mg GW870086X daily arm 3mg GW870086X daily arm may add , trial could terminate early . After screen 4 week run period prior start treatment follow period 1-2 week last dose . Approximately 120 subject complete study . Key safety assessment include ; clinical laboratory test , vital sign collection adverse event ( AE 's ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female 18 65 year A female subject eligible participate : Nonchildbearing potential . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require discontinue HRT allow confirmation postmenopausal status prior study enrollment . Male subject must agree use one protocol contraception method . Body weight , men ≥ 50 kg , woman ≥ 45 kg BMI within range 18.5 29.0 kg/m2 ( inclusive ) . Documented history bronchial asthma , first diagnose least 6 month prior screen visit currently treat intermittent shortacting beta2 agonist therapy Severity Disease : A best FEV1 60 % 85 % predict normal value Visit 1 screen period . No history smoking within 6 month start study total pack year history ≤10 pack year Capable give write informed consent Single QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . AST ALT &lt; 2xULN ; alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . A positive test Hepatitis B Hepatitis C antibody . Current chronic history liver disease , know hepatic biliary abnormality The subject positive prestudy drug/alcohol screen unless positive explain patient ' medication . Past present disease , judge investigator , may affect outcome study . Clinically significant abnormality safety laboratory analysis screening , determine investigator . Subject hypertensive screening . History lifethreatening asthma , define asthma episode require intubation and/or associate hypercapnoea , respiratory arrest and/or hypoxic seizure . Administration oral , injectable dermal steroid within 8 week screen . Exacerbation asthma within 4 week prior first dose study medication . Respiratory Infection resolve within 4 week screen lead change asthma management , opinion Investigator expect affect subject asthma status subject ability participate study . Any asthma exacerbation require oral corticosteroid within 8 week screen . A subject must hospitalisation asthma within 6 month prior screen A positive test HIV antibody . History regular alcohol consumption within 6 month study . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Paracetamol exception permit daily dos 4 g screen followup . Has take Xanthines ( include theophylline , include caffeine ) , anticholinergic , cromoglycates and/or longacting beta2 agonist within 1 week prior screen unable abstain throughout study . Unable abstain medication short act inhaled beta2 agonist paracetamol ( 4 g per day ) 7 day screen followup visit . Unable abstain medication supplement significantly inhibit cytochrome P450 subfamily enzyme CYP3A4 , screen throughout study . Unable use DISKHALER® device correctly . History sensitivity study medication . Where participation study would result donation blood blood product excess 500 ml within 56 day period . Unwillingness inability follow procedure outline protocol . The subject able understand comply protocol requirement , instruction protocol state restriction . Vulnerable subject . Subject mentally legally incapacitate . Urinary cotinine level indicative smoking history within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>GW870086</keyword>
	<keyword>Efficacy</keyword>
	<keyword>FEV1</keyword>
</DOC>